Calico Biosystems: Predicting Life-Changing Drugs for Cancer Patients
Channel: Venturelab TV
Date: 2024-01-30

Calico Biosystems' CEO and CSO, Marie-Agnès Doucey and Riccardo Turrini, are merging innovative experimental and digital approaches to assess the potency of therapeutics on patient tumors. Their experimental approach uses exclusive know-how to test therapeutics on native patient tumors, while the digital approach uses computational modeling to predict the most potent combinations of therapeutics to benefit patients.

Read more about Calico Biosystems project here: https://www.venturekick.ch/Startups-assessing-tumour-therapies-with-AI-modelling-streamlining-legislative-analysis-for-public-affairs-providing-disruptive-radio-frequency-testing-enhancing-patient-care-with-digital-solutions-and-simplifying-presentation-delivery-each-win-CHF-10000

#VentureKick #SwissStartups